BeStock  
Stocks › Biotechnology › NTLA

Intellia Therapeutics NTLA

US equityMarket cap rank #2922BiotechnologyGene Editing
$10.00 +$0.48 (+5.04%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $10.00 +0.01%
Open$9.34
Prev close$9.52
Day range$9.30 – $10.40
Volume15.19M
Market cap$1.40B
P/E (TTM)–
Dividend yield–

Fundamentals

Latest reported quarter: Q3, ended Sep 2026

Revenue$7.16M-48.0% YoY
Operating profit-$122.33M-9.7% YoY
Net profit-$127.49M-25.8% YoY
Diluted EPS-$0.91+1.1% YoY
Free cash flow-$86.32M-12.2% YoY
Operating cash flow-$85.43M

Revenue, last 8 quarters

$12.9MDec '24$16.6MMar '25$14.2MJun '25$13.8MSep '25$23.0MDec '25$15.0MMar '26$7.7MJun '26$7.2MSep '26

Net profit, last 8 quarters

$-128.9MDec '24$-114.3MMar '25$-101.3MJun '25$-101.3MSep '25$-95.8MDec '25$-96.2MMar '26$-106.6MJun '26$-127.5MSep '26

Diluted EPS by quarter

-1.27Dec '24-1.10Mar '25-0.98Jun '25-0.92Sep '25-0.83Dec '25-0.81Mar '26-0.80Jun '26-0.91Sep '26

Free cash flow by quarter

$-86.2MDec '24$-149.7MMar '25$-99.9MJun '25$-76.9MSep '25$-69.4MDec '25$-117.4MMar '26$-84.9MJun '26$-86.3MSep '26

Annual revenue

$58.0MFY20$33.1MFY21$52.1MFY22$36.3MFY23$57.9MFY24$67.7MFY25

Profitability & balance sheet

Operating margin-821.2%
Net margin-805.7%
Return on equity-62.6%
Return on assets-46.6%
Return on invested capital-53.2%
Current ratio6.31
Liabilities / assets32.1%
Cash & investments$474.11M
Total debt$209.17M
Net cash (debt)$264.95M

Income statement

Line item 2026 Q3 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4
Total Revenue as Reported $7.16M $7.66M $15.05M $67.67M $23.02M
Total Operating Revenue $7.16M $7.66M $15.05M $67.67M $23.02M
Operating Expense $129.49M $120.42M $115.58M $508.66M $121.73M
Selling and Admin Expenses $46.14M $37.82M $34.84M $119.80M $33.08M
-General & Admin Expense $46.14M $37.82M $34.84M $119.80M $33.08M
Research & Development $83.35M $82.60M $80.74M $388.86M $88.65M
Operating Profit -$122.33M -$112.76M -$100.53M -$440.99M -$98.71M
Net Non-Operating Interest Income (Expense) $5.23M $5.80M $5.21M $29.20M $6.48M
Non-Operating Interest Income $5.84M $5.80M $5.21M $29.20M $6.48M
Non-Operating Interest Expense $611,000.00 – – – –
Other Income (Expense) -$10.39M $329,000.00 -$904,000.00 -$899,000.00 -$3.55M
Gain on Sale of Security -$10.39M $329,000.00 -$904,000.00 -$899,000.00 -$3.55M
Pretax Profit -$127.49M -$106.63M -$96.23M -$412.69M -$95.79M
Net Profit -$127.49M -$106.63M -$96.23M -$412.69M -$95.79M
Profit from Continuing Operations -$127.49M -$106.63M -$96.23M -$412.69M -$95.79M
Net Income to Parent Company -$127.49M -$106.63M -$96.23M -$412.69M -$95.79M
Net Income to Common Stockholders -$127.49M -$106.63M -$96.23M -$412.69M -$95.79M
Basic EPS -$0.91 -$0.80 -$0.81 -$3.81 -$0.83
Diluted EPS -$0.91 -$0.80 -$0.81 -$3.81 -$0.83
Earnings from Equity Interest – – – $0.00 –
Special Income (Charges) – – – $0.00 –
-Less:Restructuring and Mergern & Acquisition – – – $0.00 –

Balance sheet

Line item 2026 Q3 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4
Total Assets $902.56M $857.16M $758.78M $842.13M $842.13M
Total Current Assets $506.35M $527.83M $466.45M $527.71M $527.71M
Cash and Cash Equivalents & Short-Term Investments $474.11M $437.76M $375.99M $449.88M $449.88M
-Cash and Cash Equivalents $156.10M $106.13M $134.70M $155.46M $155.46M
-Short Term Investments $318.01M $331.63M $241.29M $294.42M $294.42M
Receivables $7.50M $7.32M $9.13M $9.47M $9.47M
-Accounts Receivable $7.50M $7.32M $9.13M $9.47M $9.47M
Other Current Assets $24.74M $82.75M $81.33M $68.36M $68.36M
Total Non-Current Assets $396.21M $329.33M $292.33M $314.42M $314.42M
Net PPE $226.41M $101.01M $113.06M $123.63M $123.63M
-Gross PPE $226.41M $101.01M $113.06M $182.23M $182.23M
Investments and Advances $152.19M $212.48M $162.82M $190.79M $190.79M
-Available for Sale Securities $140.70M $190.60M $141.26M $155.25M $155.25M
Other Non-Current Assets $17.61M $15.84M $16.46M – –
Total Liabilities $289.47M $129.46M $137.84M $170.73M $170.73M
Total Current Liabilities $80.31M $79.39M $76.45M $103.88M $103.88M
Payables $12.55M $11.71M $18.80M $20.25M $20.25M
-Accounts Payable $12.55M $11.71M $18.80M $20.25M $20.25M
Current Accrued Expenses $26.47M $29.91M $28.60M $26.79M $26.79M
Short-Term Debt and Capital Lease Obligation $20.98M $23.34M $19.10M $26.48M $26.48M
-Current Capital Lease Obligation $20.98M $23.34M $19.10M $26.48M $26.48M
Current Deferred Liabilities $0.00 $0.00 $630,000.00 $7.29M $7.29M
Total Non-Current Liabilities $209.17M $50.07M $61.40M $66.85M $66.85M
Long Term Debt and Capital Lease Obligation $209.17M $50.07M $61.40M $66.85M $66.85M
-Long Term Debt $73.73M – – – –
-Long Term Capital Lease Obligation $135.43M $50.07M $61.40M $66.85M $66.85M
Total Equity $613.09M $727.71M $620.94M $671.39M $671.39M
Stockholders' Equity $613.09M $727.71M $620.94M $671.39M $671.39M
Capital Stock $14,000.00 $14,000.00 $12,000.00 $12,000.00 $12,000.00
-Common Stock $14,000.00 $14,000.00 $12,000.00 $12,000.00 $12,000.00
Additional Paid-In Capital $3.54B $3.52B $3.31B $3.26B $3.26B
Retained Earnings -$2.92B -$2.79B -$2.69B -$2.59B -$2.59B
Gains/Losses Not Affecting Retained Earnings -$2.56M -$1.03M -$240,000.00 $1.03M $1.03M
-Accumulated Depreciation – – – -$58.61M -$58.61M
Non-Current Deferred Liabilities – – – $0.00 $0.00

Cash flow

Line item 2026 Q3 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4
Operating Cash Flow -$85.43M -$83.11M -$117.35M -$394.74M -$69.29M
Net cash flow from continuing operations -$85.43M -$83.11M -$117.35M -$394.74M -$69.29M
Net Income from Continuing Operations -$127.49M -$106.63M -$96.23M -$412.69M -$95.79M
Gain/Loss from Continuing Operations -$221,000.00 – – $527,000.00 –
Depreciation & Depletion & Amortization $1.92M $2.08M $2.20M $15.92M $6.02M
Change in Working Capital $16.09M $4.15M -$37.17M -$73.75M $494,000.00
-Change in Receivables -$178,000.00 $1.81M $337,000.00 -$951,000.00 $1.58M
-Change in Prepaid Assets $3.20M -$1.42M -$12.97M -$26.35M -$8.69M
-Change in Payables and Accrued Expense $1.84M -$730,000.00 -$13.37M $716,000.00 $15.99M
-Change in Other Current Assets $10.29M $10.12M $8.34M $35.90M $10.23M
-Change in Other Current Liabilities $940,000.00 -$5.00M -$12.84M -$54.95M -$4.64M
-Change In Other Working Capital $0.00 -$630,000.00 -$6.66M -$28.11M -$13.98M
Net cash flow from investing $61.94M -$141.57M $66.31M $228.03M $27.53M
Net Cash Flow from Continuing Investing Activities $61.94M -$141.57M $66.31M $228.03M $27.53M
Net PPE Purchase and Sale -$621,000.00 -$1.72M -$79,000.00 -$1.13M -$126,000.00
Net Investment Purchase and Sale $62.56M -$139.85M $66.39M $229.16M $27.66M
Financing Cash Flow $73.46M $196.12M $33.57M $131.49M $1.98M
Net Cash Flow from Continuing Financing Activities $73.46M $196.12M $33.57M $131.49M $1.98M
Net Common Stock Issuance $0.00 $194.58M $33.57M $128.18M $0.00
Proceeds from Stock Option Exercised $0.00 – – $3.31M $1.98M
Ending Cash Balance $171.50M $121.53M $150.10M $167.57M $167.57M
Net Change in Cash $49.97M -$28.57M -$17.47M -$35.22M -$39.77M
Beginning Cash Balance $121.53M $150.10M $167.57M $202.79M $207.34M
Free Cash Flow -$86.32M -$84.92M -$117.43M -$395.87M -$69.41M

Discussion

No comments yet — be the first to weigh in on NTLA.

Sign in to join the discussion.

Scroll to Top